Wednesday, January 07, 2026 The ICC.1: NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study trial has permanently closed. The letter of permanent trial closure/termination can be found in the members' area of the CCTG webpage under "Toolbox-Reports-Trial Closure" here: https://www.ctg.queensu.ca/trials/permanent_closure/permanent-trial-closureIn this prospective cohort study of 1572 adults with cancer and a positive SARS-CoV-2 test result, the cumulative incidence of COVID-19–specific death in the first 90 days was highest in patients with lymphoma, intermediate in patients with acute leukemia and lung cancer, and lowest in patients with other solid tumors and other hematologic cancers. Primary Publication:Rini, Brian I.; Best, Ana F.; Bowman, Mel D.; Mishkin, Grace E.; Denicoff, Andrea M.; Rubinstein, Larry V.; Harris, Lyndsay; Geiger, Ann M.; Mark, Nicholas M.; Pergam, Steven A.; Warner, Jeremy L.; Khorana, Alok A.; Gnjatic, Sacha; Yen, Tina W.F.; Liles, Darla K.; Bestvina, Christine M.; Shah, Neil J.; Norrell, Jacqueline T.; Hershman, Dawn L.; Holter-Chakrabarty, Jennifer L.; Poklepovic, Andrew S.; Chanock, Stephen J.; Sankaran, Hari; Korde, Larissa A.; Risk Factors for COVID-19¿Related Hospitalization and Death in Patients With Cancer: The National Cancer Institute COVID-19 in Cancer Patients Study (NCCAPS) (ONLINE)JAMA OncologyJAMA Oncology:ONLINE, 2025 Clinicaltrials.gov Results Reporting: NCT04387656
